Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on Urothelial/Bladder Cancer (Jun 2019)

Posted by Matt Breese on Jun 7, 2019

Find me on:

According to our recent payer coverage analysis for urothelial/bladder cancer treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for urothelial/bladder cancer treatments shows that under the pharmacy benefit, about 24% of the lives under commercial formularies are covered with utilization management restrictions.

MMIT-Reality Check-Urothelial Bladder Cancer_2Q2019Data snapshot as of Q2 2019

Trends: In April 2019, the FDA gave accelerated approval to the Janssen Pharmaceutical Companies of Johnson & Johnson's Balversa (erdafitinib).

To read the full Reality Check on Urothelial/Bladder Cancer treatments with key findings on clinical characteristics, drug market access and payer coverage, please click on the button below: 


View Reality Check

Topics: Specialty, Market Access, Payer, Branding & Marketing